A1E94

Eliglustat

Created:	2026-05-18
Last modified:	2026-09-02

Find Related PDB Entry
1 entries where A1E94 is found as a standalone ligand

Find related ligands: Help
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	65
Chiral Atom Count	2
Bond Count	67
Aromatic Bond Count	6

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	Eliglustat
Systematic Name (OpenEye OEToolkits)	~{N}-[(1~{R},2~{R})-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-oxidanyl-3-pyrrolidin-1-yl-propan-2-yl]octanamide
Formula	C₂₃ H₃₆ N₂ O₄
Molecular Weight	404.543
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	CACTVS	3.385	CCCCCCCC(=O)N[CH](CN1CCCC1)[CH](O)c2ccc3OCCOc3c2
SMILES	OpenEye OEToolkits	2.0.7	CCCCCCCC(=O)NC(CN1CCCC1)C(c2ccc3c(c2)OCCO3)O
Canonical SMILES	CACTVS	3.385	CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c2ccc3OCCOc3c2
Canonical SMILES	OpenEye OEToolkits	2.0.7	CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](c2ccc3c(c2)OCCO3)O
InChI	InChI	1.06	InChI=1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)/t19-,23-/m1/s1
InChIKey	InChI	1.06	FJZZPCZKBUKGGU-AUSIDOKSSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank ID	DB09039
Name	Eliglustat
Description	Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide.[L41404] Eliglustat is mainly metabolized by CYP2D6.[L41404] Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634]
Synonyms	Eliglustat Eliglustatum éliglustat N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamide Eliglustat tartrate
Indication	Eliglustat is a glucosylceramide synthase inhibitor indicated for the long-term treatment of type 1 Gaucher disease in adult patients who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.[L41404] CYP2D6 ultra-rapid metabolizers may not achieve adequate eliglustat concentrations to achieve a therapeutic effect. A specific dosage cannot be recommended for CYP2D6 indeterminate metabolizers.[L41404]
Categories	Alimentary Tract and Metabolism Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) Cytochrome P-450 CYP2D6 Substrates Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Enzyme Inhibitors Gaucher Disease Glucosylceramide Synthase Inhibitor Glucosylceramide Synthase Inhibitors Highest Risk QTc-Prolonging Agents Other Miscellaneous Therapeutic Agents P-glycoprotein inhibitors P-glycoprotein substrates QTc Prolonging Agents Various Alimentary Tract and Metabolism Products
ATC-Code	A16AX10
CAS number	491833-29-5

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

Name	Target Sequence	Pharmacological Action	Actions
Ceramide glucosyltransferase	MALLDLALEGMAVFGFVLFLVLWLMHFMAIIYTRLHLNKKATDKQPYSKL...	unknown	inhibitor
Cytochrome P450 2D6	MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD...	unknown	substrate,inhibitor
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
P-glycoprotein 1	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...	unknown	substrate,inhibitor

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682